The DOI matches its Crossref record, with a small difference in title or year; 59 of the 60 references it cites were found in a registry or an index.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
Open accessAbstract
The Huntington's disease (HD) gene has been mapped in 4p16.3 but has eluded identification. We have used haplotype analysis of linkage disequilibrium to spotlight a small segment of 4p16.3 as the likely location of the defect. A new gene, IT15, isolated using cloned trapped exons from the target area contains a polymorphic trinucleotide repeat that is expanded and unstable on HD chromosomes. A (CAG)n repeat longer than the normal range was observed on HD chromosomes from all 75 disease families examined, comprising a variety of ethnic backgrounds and 4p16.3 haplotypes. The (CAG)n repeat appears to be located within the coding sequence of a predicted approximately 348 kd protein that is widely expressed but unrelated to any known gene. Thus, the HD mutation involves an unstable DNA segment, similar to those described in fragile X syndrome, spino-bulbar muscular atrophy, and myotonic dystrophy, acting in the context of a novel 4p16.3 gene to produce a dominant phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Huntington’s Disease arises from an expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the HTT gene (formerly IT15) of chromosome 4p16.3, leading to the production of a dysfunctional huntingtin protein (polyQ-HTT) [161,162].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [162]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HD is usually confirmed diagnostically through the identification of 36 or more CAG repeats on the short arm of chromosome 4p16.3 in the Huntingtin gene [162].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [162]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HD etiology is entirely due to autosomal-dominant HTT mutations with abnormal CAG repeat expansion in exon 1, producing mutant huntingtin protein that aggregates and leads to neurodegeneration (379).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [379]
Experimental — accuracy not yet measuredIn the citing paper
“The cause of Huntington's disease, an autosomal dominant neurological disorder, is well established as an abnormal expansion of CAG triplet repeats in exon 1 of the ubiquitously expressed huntingtin ( HTT ) gene, resulting in an elongated polyglutamine (Q) tract in the mutant huntingtin protein (mHTT) (MacDonald et al. , 1993).”
From Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease (2020) · cites this paper as MacDonald et al., 1993
In the citing paper
“In Huntington disease, poly-glutamine-expanded mHTT aggregates and accumulates194”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [194]
In the citing paper
“Huntington’s disease (HD) is an inherited disorder caused by a CAG trinucleotide repeat expansion in HTT which leads to progressive motor and cognitive impairment due to the gradual loss of neurons within striatal and cortical brain regions [1].”
From miR-10b-5p expression in Huntington’s disease brain relates to age of onset and the extent of striatal involvement (2015) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. L., Wilson, E. M., Lubahn, D. B., Harding, A., & Fischbeck, K. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,801
Brook, J. D., McCurrach, M. E., Harley, H. G., Buckler, A., Church, D. M., Aburatani, H., Hunter, K. W., Stanton, V. P., Thirion, J., Hudson, T. J., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90154-5 · Cited by 2,754
A polymorphic DNA marker genetically linked to Huntington's disease
Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., Watkins, P. C., Ottina, K. A., Wallace, M. R., Sakaguchi, A. Y., et al. (1983) · Nature · doi:10.1038/306234a0 · Cited by 2,340
Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., Verkert, A. J. M. H., Holden, J. J. A., Fenwick, R. G., Warren, S. T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90283-5 · Cited by 2,080
Myotonic Dystrophy Mutation: an Unstable CTG Repeat in the 3′ Untranslated region of the Gene
Mahadevan, M. S., Tsilfidis, C., Sabourin, L. A., Shutler, G., Amemiya, C. T., Jansen, G., Neville, C., Narang, M. A., Barceló, J. M., O'Hoy, K., et al. (1992) · Science · doi:10.1126/science.1546325 · Cited by 1,656
Absence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
An Unstable Triplet Repeat in a Gene Related to Myotonic Muscular Dystrophy
Fu, Y., Pizzuti, A., Fenwick, R. G., King, J., Rajnarayan, S., Dunne, P. W., Dubel, J., Nasser, G. A., Ashizawa, T., de Jong, P., et al. (1992) · Science · doi:10.1126/science.1546326 · Cited by 1,453
Research works printed but not linked: 2
- Gusella, J. F., Varsanyi-Breiner, A., Kao, F. T.. Jones, C., Puck, T. T., Keys, C., Orkin, S., and Housman, D. E. (1979). Precise localiza- tion of the human @globin gene complex on chromosome 11. Proc. Natl. Acad. Sci. USA 76, 5239-5243.
- Lehrach, H., Drmanac, R.. Hoheisel, J., Larin, Z., Lennon, G., Nizetic, D., Monaco, A., Zehetner, G., and Poustka, A. (1990). Hybridisation fingerprinting in genome mapping and sequencing. In Genome Analy- sis: Genetic and Physical Mapping, Volume 1, K. E. Davies and S. M. Tighlman, eds. (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press), pp. 39-81.
Cited by
Sorted by citations
Items 701–800 of 1,087
Grady, D. L., Chi, H.-C., Ding, Y.-C., Smith, M., Wang, E., Schuck, S. E. B., Flodman, P. L., Spence, M. A., Swanson, J. M., & Moyzis, R. K. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001350 · Cited by 181
Pérez‐Severiano, F., Santamarı́a, A., Pedraza‐Chaverrí, J., Medina‐Campos, O. N., Rı́os, C., & Segovia, J. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000018843.83770.4b · Cited by 181
Steele, A. D., Jackson, W. S., King, O. D., & Lindquist, S. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610779104 · Cited by 180
Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin
Chen, N., Luo, T., Wellington, C. L., Metzler, M., McCutcheon, K. M., Hayden, M. R., & Raymond, L. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721890.x · Cited by 183
Nuclear Accumulation of Truncated Atrophin-1 Fragments in a Transgenic Mouse Model of DRPLA
Schilling, G., Wood, J., Duan, K., Slunt, H. H., Gonzales, V., Yamada, M., Cooper, J. K., Margolis, R. L., Jenkins, N. A., Copeland, N. G., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80839-9 · Cited by 181
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
The selective vulnerability of nerve cells in Huntington's disease
Sieradzan, K. A., & Mann, D. M. A. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2001.00299.x · Cited by 184
Schweitzer, J. K., & Livingston, D. M. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.69 · Cited by 180
Waragai, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.6.977 · Cited by 180
Cognitive disorders and neurogenesis deficits in Huntington’s disease mice are rescued by fluoxetine
Grote, H. E., Bull, N. D., Howard, M. L., Van Dellen, A., Blakemore, C., Bartlett, P. F., & Hannan, A. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04365.x · Cited by 179
The endocannabinoid system as a target for the treatment of neurodegenerative disease
Scotter, E. L., Abood, M. E., & Glass, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00735.x · Cited by 188
AAV-Mediated gene delivery of BDNF or GDNF is neuroprotective in a model of huntington disease
Kells, A. P., Fong, D. M., Dragunow, M., During, M. J., Young, D., & Connor, B. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.02.016 · Cited by 179
Zhai, W., Jeong, H., Cui, L., Krainc, D., & Tjian, R. (2005) · Cell · doi:10.1016/j.cell.2005.10.030 · Cited by 179
Targeting H3K4 trimethylation in Huntington disease
Vashishtha, M., Ng, C., Yildirim, F., Gipson, T. A., Kratter, I. H., Bodai, L., Song, W., Lau, A., Labadorf, A. T., Ciernia, A. V., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311323110 · Cited by 188
Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease
Augood, S. J., Faull, R. L. M., & Emson, P. C. (1997) · Annals of Neurology · doi:10.1002/ana.410420213 · Cited by 179
Psychological costs and benefits of predictive testing for Huntington's disease
Codori, A., & Brandt, J. (1994) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320540304 · Cited by 179
Wang, J., Ginés, S., MacDonald, M. E., & Gusella, J. F. (2005) · BMC Neuroscience · doi:10.1186/1471-2202-6-1 · Cited by 180
Self-citationTakano, H., & Gusella, J. F. (2002) · BMC Neuroscience · doi:10.1186/1471-2202-3-15 · Cited by 179
In-Vivo Electrochemistry: What Can We Learn about Living Systems?
Wilson, G. S., & Johnson, M. A. (2008) · Chemical Reviews · doi:10.1021/cr068082i · Cited by 178
Zajac, M. S., Pang, T. Y., Wong, N. C., Weinrich, B., Leang, L., Craig, J. M., Saffery, R., & Hannan, A. J. (2009) · Hippocampus · doi:10.1002/hipo.20658 · Cited by 184
Pollock, K., Dahlenburg, H., Nelson, H., Fink, K. D., Cary, W., Hendrix, K. J., Annett, G., Torrest, A., Deng, P., Gutierrez, J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.12 · Cited by 178
Protein-coding repeat polymorphisms strongly shape diverse human phenotypes
Mukamel, R. E., Handsaker, R. E., Sherman, M. A., Barton, A. R., Zheng, Y., McCarroll, S. A., & Loh, P.-R. (2021) · Science · doi:10.1126/science.abg8289 · Cited by 178
Neuroinflammation in Huntington’s disease
Möller, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0430-7 · Cited by 180
Cystamine Inhibits Caspase Activity
Lesort, M. J., Lee, M., Tucholski, J., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205812200 · Cited by 177
Richfield, E. K., & Herkenham, M. A. (1994) · Annals of Neurology · doi:10.1002/ana.410360406 · Cited by 177
Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease
Schwarcz, R. M., Guidetti, P., Sathyasaikumar, K. V., & Muchowski, P. J. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.005 · Cited by 177
Hypothalamic–endocrine aspects in Huntington's disease
Petersén, Å., & Björkqvist, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04985.x · Cited by 176
Riluzole in Huntington's disease: a 3‐year, randomized controlled study
Landwehrmeyer, G. B., Dubois, B., de Yébenes, J. G., Kremer, B. P. H., Gaus, W., Kraus, P. H., Przuntek, H., Dib, M., Doble, A., Fischer, W., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21181 · Cited by 176
Huntington's disease: The current state of research with peripheral tissues
Sassone, J., Colciago, C., Cislaghi, G., Silani, V., & Ciammola, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.012 · Cited by 175
Glutamate-based therapeutic approaches: NR2B receptor antagonists
Gogas, K. R. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.001 · Cited by 175
Wilton, D. K., Mastro, K. J., Heller, M. D., Gergits, F. W., Willing, C. R., Fahey, J. B., Frouin, A., Daggett, A., Gu, X., Kim, Y. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02566-3 · Cited by 189
Ryu, J. K., Kim, J., Cho, S. J., Hatori, K., Nagai, A., Choi, H. B., Lee, M. C., McLarnon, J. G., & Kim, S. U. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.016 · Cited by 175
Huntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing
Rigamonti, D., Sipione, S., Goffredo, D., Zuccato, C., Fossale, E., & Cattaneo, E. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100044200 · Cited by 175
CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model
Chou, S., Lee, Y., Chen, H., Chiang, M., Lai, H., Chang, H., Wu, Y., Sun, C., Chien, C., Lin, Y., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03029.x · Cited by 179
Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles
Carter, A. J. R., & Nguyen, A. Q. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-160 · Cited by 176
Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
Chen, J., Marks, E. S., Lai, B. C. H., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S. M., & Fox, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077023 · Cited by 176
Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.
Gaughwin, P. M., Ciesla, M., Lahiri, N., Tabrizi, S. J., Brundin, P., & Björkqvist, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr111 · Cited by 145
Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease
Quintanilla, R. A., & Johnson, G. V. W. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.010 · Cited by 176
Tissue transglutaminase: a possible role in neurodegenerative diseases
Lesort, M. J., Tucholski, J., Miller, M. L., & Johnson, G. V. W. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00052-0 · Cited by 173
Ocular motor abnormalities in Huntington's disease
Lasker, A. G., & Zee, D. S. (1997) · Vision Research · doi:10.1016/s0042-6989(96)00169-1 · Cited by 174
Complex I Defect in muscle from patients with Huntington's disease
Arenas, J., Campos, Y., Ribacoba, R., Martín, M. A., Rubio‐Terres, C., Ablanedo, P., & Cabello, A. (1998) · Annals of Neurology · doi:10.1002/ana.410430321 · Cited by 174
Boll, M.-C., Alcaraz-Zubeldia, M., Montes, S., & Rios, C. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9610-3 · Cited by 173
ADF/Cofilin-Actin Rods in Neurodegenerative Diseases
Bamburg, J. R., Bernstein, B. W., Davis, R. C., Flynn, K. C., Goldsbury, C., Jensen, J. R., Maloney, M. T., Marsden, I. T., Minamide, L. S., Pak, C. W., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791050902 · Cited by 173
Camnasio, S., Carri, A. D., Lombardo, A., Grad, I., Mariotti, C., Castucci, A., Rozell, B., Riso, P. L., Castiglioni, V., Zuccato, C., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.042 · Cited by 175
Cancer and Neurodegeneration: Between the Devil and the Deep Blue Sea
Plun‐Favreau, H., Lewis, P. A., Hardy, J., Martins, L. M., & Wood, N. W. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001257 · Cited by 176
Labbadia, J. P., Cunliffe, H. E., Weiss, A., Katsyuba, E., Sathasivam, K., Seredenina, T. S., Woodman, B., Moussaoui, S. M., Frentzel, S., Luthi‐Carter, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57413 · Cited by 172
Han, I., You, Y., Kordower, J. H., Brady, S. T., & Morfini, G. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06672.x · Cited by 176
Kazantsev, A. G., Walker, H. A., Slepko, N., Bear, J. E., Preisinger, E., Steffan, J. S., Zhu, Y.-Z., Gertler, F. B., Housman, D. E., Marsh, J., et al. (2002) · Nature Genetics · doi:10.1038/ng864 · Cited by 173
Apostol, B. L., Kazantsev, A., Raffioni, S., Illes, K., Pallos, J., Bodai, L., Slepko, N., Bear, J. E., Gertler, F. B., Hersch, S. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2628045100 · Cited by 173
Vercruysse, P., Vieau, D., Blum, D., Petersén, Å., & Dupuis, L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00002 · Cited by 172
Hebb, A. L. O., Robertson, H. A., & Denovan‐Wright, E. M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.11.009 · Cited by 172
Phosphorylation of Threonine 3
Aiken, C. T., Steffan, J. S., Guerrero, C., Khashwji, H., Lukácsovich, T., Simmons, D. A., Purcell, J., Menhaji, K., Zhu, Y., Green, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.013193 · Cited by 172
Therapeutic interventions for symptomatic treatment in Huntington's disease
Mestre, T., Ferreira, J. J., Coelho, M. M., Rosa, M. M., & Sampaio, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006456.pub2 · Cited by 173
Martín-Aparicio, E., Yamamoto, A., Hernández, F., Hen, R., Ávila, J., & Lucas, J. J. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-22-08772.2001 · Cited by 168
Zeron, M. M., Fernandes, H. B., Krebs, C., Shehadeh, J., Wellington, C. L., Leavitt, B. R., Baimbridge, K. G., Hayden, M. R., & Raymond, L. A. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.11.014 · Cited by 170
Resveratrol: A Focus on Several Neurodegenerative Diseases
Tellone, E., Galtieri, A., Russo, A., Giardina, B., & Ficarra, S. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/392169 · Cited by 177
Klöppel, S., Draganski, B., Golding, C. V. P., Chu, C., Nagy, Z., Cook, P. A., Hicks, S. L., Kennard, C., Alexander, D. C., Parker, G. J. M., et al. (2007) · Brain · doi:10.1093/brain/awm275 · Cited by 173
Sandhir, R., & Mehrotra, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.018 · Cited by 171
Detecting epistatic interactions contributing to quantitative traits
Culverhouse, R., Klein, T., & Shannon, W. D. (2004) · Genetic Epidemiology · doi:10.1002/gepi.20006 · Cited by 171
de Yébenes, J. G., Landwehrmeyer, G. B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R. A., Carsten Saft, C., Magnet, M. K., Sword, A., Rembratt, Å., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70233-2 · Cited by 171
Romero, E., Cha, G., Verstreken, P., Ly, C. V., Hughes, R. E., Bellen, H. J., & Botas, J. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.025 · Cited by 170
Salivary biomarkers for the diagnosis and monitoring of neurological diseases
Farah, R., Haraty, H., Salame, Z., Fares, Y., Ojcius, D. M., & Sadier, N. S. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.03.004 · Cited by 175
Genetics of restless legs syndrome
Winkelmann, J., Schormair, B., Xiong, L., Dion, P. A., Rye, D. B., & Rouleau, G. A. (2002) · Elsevier eBooks · doi:10.1007/s11910-008-0033-y · Cited by 175
Vitamin E and Neurodegenerative Disorders Associated with Oxidative Stress
Butterfield, D. A., Castegna, A., Drake, J., Scapagnini, G., & Calabrese, V. (2002) · Nutritional Neuroscience · doi:10.1080/10284150290028954 · Cited by 172
Low brain‐derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients
Ciammola, A., Sassone, J., Cannella, M., Calza, S., Poletti, B., Frati, L., Squitieri, F., & Silani, V. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30501 · Cited by 178
McMahon, F. J., Stine, O. C., Chase, G. A., Meyers, D. A., Simpson, S. G., & DePaulo, J. R. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.2.210 · Cited by 171
Ramos, R. G. P., Igloi, G. L., Lichte, B., Baumann, U., Maier, D., Schneider, T., Brandstätter, J. H., Fröhlich, A., & Fischbach, K. F. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2533 · Cited by 171
Alterations in Cortical Excitation and Inhibition in Genetic Mouse Models of Huntington's Disease
Cummings, D. M., André, V., Uzgil, B., Gee, S. M., Fisher, Y. E., Cepeda, C., & Levine, M. S. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1592-09.2009 · Cited by 167
Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A. C., Syed, A., Purcell, J. M., Chen, Y., Sharma, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.016 · Cited by 173
Neurodegenerative processes in Huntington's disease
Bano, D., Zanetti, F., Mende, Y., & Nicotera, P. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.112 · Cited by 173
Quantitative neuropathological changes in presymptomatic Huntington's disease
Gómez‐Tortosa, E., MacDonald, M. E., Friend, J. C., Taylor, S. A., Weiler, L., Cupples, L. A., Srinidhi, J., Gusella, J. F., Bird, E. D., Vonsattel, J., et al. (2001) · Annals of Neurology · doi:10.1002/1531-8249(200101)49:1 · Cited by 174
Self-citationDedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169
Neural stem cell‐based treatment for neurodegenerative diseases
Kim, S. U., Lee, H. J., & Kim, Y. B. (2013) · Neuropathology · doi:10.1111/neup.12020 · Cited by 177
Joshi, P. R., Wu, N.-P., André, V. M., Cummings, D. M., Cepeda, C., Joyce, J. A., Carroll, J. B., Leavitt, B. R., Hayden, M. R., Levine, M. S., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5687-08.2009 · Cited by 173
Lee, J.-H., Kosaras, B., Signore, S. J. D., Cormier, K., McKee, A. C., Ratan, R. R., Kowall, N. W., & Ryu, H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0788-5 · Cited by 170
Bohanna, I., Georgiou‐Karistianis, N., Hannan, A. J., & Egan, G. F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.04.001 · Cited by 169
Dey, N. D., Bombard, M. C., Roland, B. P., Davidson, S., Lü, M., Rossignol, J., Sandstrom, M. I., Skeel, R. L., Lescaudron, L., & Dunbar, G. L. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.023 · Cited by 169
The Function of Autophagy in Neurodegenerative Diseases
Kiriyama, Y., & Nochi, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125990 · Cited by 178
Automated deformation analysis in the YAC128 Huntington disease mouse model
Lerch, J. P., Carroll, J. B., Spring, S., Bertram, L. N., Schwab, C., Hayden, M. R., & Henkelman, R. M. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.08.033 · Cited by 164
The mitochondrial permeability transition in neurologic disease
Norenberg, M. D., & RAO, K. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.02.008 · Cited by 168
Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts
Moghaddam, K. H., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26583 · Cited by 173
Chintalaphani, S. R., Pineda, S. S., Deveson, I. W., & Kumar, K. R. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01201-x · Cited by 177
Denovan‐Wright, E. M., & Robertson, H. A. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00157-3 · Cited by 168
Johansson, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.171 · Cited by 169
Waelter, S. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1807 · Cited by 169
Paulsen, J. S., Nance, M., Kim, J.-I., Carlozzi, N. E., Panegyres, P. K., Erwin, C., Goh, A., McCusker, E., & Williams, J. K. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.08.003 · Cited by 168
Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants
Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 169
Sathasivam, K., Lane, A., Legleiter, J. A., Warley, A., Woodman, B., Finkbeiner, S. M., Paganetti, P., Muchowski, P. J., Wilson, S., & Bates, G. P. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp467 · Cited by 166
MicroRNAs in Neurodegenerative Diseases
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.04.002 · Cited by 168
The selective vulnerability of striatopallidal neurons
Mitchell, I., Cooper, A. J., & Griffiths, M. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00019-2 · Cited by 170
Ikeuchi, T., Koide, R., Tanaka, H., Onodera, O., Igarashi, S., Takahashi, H., Kondo, R., Ishikawa, A., Tomoda, A., Miike, T., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370610 · Cited by 168
Beyond the Qs in the polyglutamine diseases: Table 1.Preprint
Orr, H. T. (2001) · Genes & Development · doi:10.1101/gad.888401 · Cited by 168
Creighton, S., Almqvist, E. W., MacGregor, D., Fernandez, B., Hogg, H., Beis, J., Welch, J., Riddell, C., Lokkesmoe, R., Khalifa, M. M., et al. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00093.x · Cited by 167
Ehrlich, M. E. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0112-2 · Cited by 170
Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice
Gil‐Mohapel, J., Mohapel, P., Araújo, I. M., Popović, N., Li, J., Brundin, P., & Petersén, Å. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.006 · Cited by 175
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
Guidetti, P., Bates, G. P., Graham, R. K., Hayden, M. R., Leavitt, B. R., MacDonald, M. E., Slow, E., Wheeler, V. C., Woodman, B., & Schwarcz, R. M. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.011 · Cited by 166
Self-citationIn vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease
Fennema‐Notestine, C., Archibald, S. L., Jacobson, M. W., Corey‐Bloom, J., Paulsen, J. S., Peavy, G. M., Gamst, A. C., Hamilton, J. M., Salmon, D. P., & Jernigan, T. L. (2004) · Neurology · doi:10.1212/01.wnl.0000138434.68093.67 · Cited by 168
Valenza, M., Leoni, V., Karasinska, J. M., Petricca, L., Fan, J., Carroll, J., Pouladi, M. A., Fossale, E., Nguyen, H. P., Riess, O., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0917-10.2010 · Cited by 166
Self-citation
Metadata
- Authors
- MACDONALD, M.
- Affiliations
- Harvard University (US)
- Corresponding author
- MACDONALD, M
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1993-03
- Volume
- 72
- Issue
- 6
- Pages
- 971-983
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2121642311
- Semantic Scholar
- 47661acc507387c5d4de447493481bb376f88728
- Cited by
- 8,366
- References
- 60
- Citations by year
- 2026: 181 · 2025: 272 · 2024: 303 · 2023: 271 · 2022: 293 · 2021: 361 · 2020: 310 · 2019: 275 · 2018: 341 · 2017: 287 · 2016: 329 · 2015: 290 · 2014: 323 · 2013: 328 · 2012: 313
- FWCI
- 77.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- W. M. Keck Foundation
- Dana Foundation
- Hereditary Disease Foundation
- Bristol-Myers Squibb
- Wellcome Trust
- National Institutes of Health (5r01ns025631-06)
- Medical Research Council
- National Institute of Neurological Disorders and Stroke (R01NS022031, NS25631, NS 16367, NS22031)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- Huntington's disease, trinucleotide repeat expansion, CAG repeat, IT15 gene, chromosome 4p16.3, haplotype analysis, linkage disequilibrium, repeat instability, fragile X syndrome, myotonic dystrophy, gene mapping
- MeSH terms
- Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 4, Cloning, Molecular, Exons, Genes, Humans, Huntington Disease, Molecular Sequence Data, Mutation, Oligodeoxyribonucleotides, Pedigree, Polymorphism, Genetic, Repetitive Sequences, Nucleic Acid, RNA, Messenger, Restriction Mapping, Gene Expression, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
